Marshall Edwards, Inc. Raises a Total of Approximately $18 Million in Private Equity Financings; Enters Into $15 Million Equity
July 12 2006 - 7:15PM
PR Newswire (US)
WASHINGTON and SYDNEY, Australia, July 12 /PRNewswire-FirstCall/ --
Marshall Edwards, Inc. (NASDAQ:MSHL) announced today that it
entered into a definitive agreement for an approximately $4 million
private placement consisting of 1,379,310 shares of common stock
and warrants to purchase 482,759 shares of common stock at a
purchase price of $2.90 per unit. The warrants are exercisable
beginning January 11, 2007 and ending on July 11, 2010. The
exercise price of the warrants is $4.35 per share. Such $4 million
private placement is in addition to the approximately $14 million
private placement announced earlier today. Janney Montgomery Scott
LLC acted as placement agent for the private placements. In
addition, Marshall Edwards entered into a standby equity
distribution agreement with Cornell Capital Partners, LP pursuant
to which Cornell Capital has committed to purchase up to
$15,000,000 of shares of common stock from Marshall Edwards at a
discount to be calculated at the time of issuance. The standby
equity distribution agreement provides that Marshall Edwards may,
at its sole option, require Cornell Capital to purchase shares of
its common stock in increments of up to $1,500,000 over a period of
24 months once a resale registration statement covering the subject
shares of common stock is effective. In connection with the standby
equity distribution agreement, Marshall Edwards issued 600,000
warrants covering an equal number of shares on the same terms as
the warrants issued in the private placement described above and
123,326 shares of common stock to Cornell Capital in a private
placement as a commitment fee. Marshall Edwards has agreed to file
a resale registration statement in connection with the private
placement and the standby equity distribution agreement. Marshall
Edwards intends to use the proceeds from the private placement to
fund certain clinical trials and pre-clinical development and for
general corporate purposes. About Marshall Edwards, Inc. Marshall
Edwards, Inc. is a US clinical development oncology company and is
majority owned by Novogen Limited (NASDAQ:NVGN)(ASX:NRT), an
Australian biotechnology company specializing in the development of
a range of therapeutics across the fields of oncology,
cardiovascular disease and inflammatory diseases. More information
on the Novogen group of companies can be found at
http://www.marshalledwardsinc.com/ and http://www.novogen.com/.
This news release does not constitute an offer to sell or the
solicitation of an offer to buy any securities. The common stock
and warrants sold in the offering have not been registered under
the Securities Act of 1933, as amended (the "Securities Act"), or
any state securities laws and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration requirements under the Securities Act or applicable
state securities laws. Under U.S. law, a new drug cannot be
marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: Christopher Naughton - CEO of Marshall Edwards, Inc.,
+612 8877 6196; David Sheon of SciWords, LLC, +1-202-518-6321 Web
site: http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024